Stellar Biotechnologies, Inc.
322 E. Scott Street
Port Hueneme, California 93041
May 7, 2018
VIA EDGAR
United States Securities and Exchange Commission
Attention: Ada D. Sarmento and Suzanne Hayes
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Stellar Biotechnologies, Inc. Registration Statement on Form S-1 Filed April 17, 2018 File No. 333-224314 |
Dear Mses. Sarmento and Hayes,
This letter sets forth the responses of Stellar Biotechnologies, Inc. (the “Company”) to the comment set forth in your letter dated May 1, 2018, with respect to the above-referenced Registration Statement on Form S-1. For ease of reference, our response correlates with the Staff’s comment, which we provided immediately preceding the Company’s response.
Registration Statement on Form S-1
Cover Page
| 1. | Please revise the cover page to provide the date that the offering will end. Refer to Item 501(b)(8)(iii) of Regulation S-K. |
Company Response:
The Company acknowledges the Staff’s comment and notes that it will revise the outside cover page of the prospectus included in the Company’s Registration Statement on Form S-1 to add a new sentence at the end of the first full paragraph under the pricing table to reflect that the offering is expected to end on or before May 17, 2018.
If you have any questions regarding this request, please contact the undersigned at (805) 488-2800 or Barbara Jones of Greenberg Traurig, LLP at (617) 310-6064.
| Sincerely, | ||
| STELLAR BIOTECHNOLOGIES, INC. | ||
| By: | /s/ Kathi Niffenegger | |
| Name: | Kathi Niffenegger | |
| Title: | Chief Financial Officer | |
